Table 2.

The univariate and multivariate analysis of clinicopathological features and recurrence‐free survival in breast cancer patients

Variables		Univariate analysis		Multivariate analysis
		HR (95% CI a) )	p value	HR (95% CI)	p‐value
Age	<49	Ref.		Ref.
	≥50	1.192 (0.617–2.302)	0.601	0.888 (0.386–2.043)	0.780
Menopause status	No	Ref.		Ref.
	Yes	1.216 (0.627–2.359)	0.563	0.999 (0.423–2.359)	0.998
Grade	I	Ref.		Ref.
	II	7996.83 (0.000–)	0.914	3419.004 (0–)	0.912
	III	10193.7 (0.000–)	0.912	3423.619 (0–)	0.912
TNM stage	I	Ref.		Ref.
	II	1.736 (0.738–4.085)	0.206	1.834 (0.722–4.660)	0.202
	III	3.946 (1.251–12.45)	0.019	6.756 (1.854–24.63)	0.004
	IV	7.234 (1.868–28.02)	0.004	12.18 (2.808–52.80)	0.001
Tumor size (cm)	≤2	Ref.		Ref.
	>2 and ≤5	1.115 (0.569–2.185)	0.751	1.108 (0.518–2.372)	0.791
	>5	1.703 (0.393–7.379)	0.476	2.208 (0.459–10.62)	0.323
LN status	Negative	Ref.		Ref.
	Positive	1.030 (0.536–1.980)	0.929	1.074 (0.510–2.265)	0.850
ER b)	Negative	Ref.		Ref.
	Positive	0.426 (0.206–0.884)	0.022	0.701 (0.192–2.558)	0.591
PR c)	Negative	Ref.		Ref.
	Positive	0.466 (0.225–0.966)	0.040	0.333 (0.158–2.130)	0.412
Her2 d)	Negative	Ref.		Ref.
	Positive	2.217 (0.865–5.650)	0.098	3.003 (1.414–6.369)	0.004
HTR1A	Low	Ref.		Ref.
	High	0.502 (0.247–1.021)	0.057	0.406 (0.198–0.832)	0.014

^a) CI: confidence interval

^b) ER: estrogen receptor

^c) PR: progesterone receptor

^d) Her2: epidermal growth factor receptor 2.